Accesso libero

The impact of factor infusion frequency on health-related quality of life in people with haemophilia

Gabriel Pedra
Gabriel Pedra
, 
Pia Christoffersen
Pia Christoffersen
, 
Kate Khair
Kate Khair
, 
Xin Ying Lee
Xin Ying Lee
, 
Sonia O’Hara
Sonia O’Hara
, 
Jamie O’Hara
Jamie O’Hara
 e 
John Pasi
John Pasi
   | 15 ago 2020
The Journal of Haemophilia Practice's Cover Image
INFORMAZIONI SU QUESTO ARTICOLO
Articolo precedente
Articolo Successivo
Cita
Article Category: Clinical Research
Pubblicato online: 15 ago 2020
Pagine: 102 - 109
DOI: https://doi.org/10.17225/jhp00158
Parole chiave
© 2020 Gabriel Pedra et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Fig. 1

The impact of infusion frequency on health-related quality of life in people with haemophilia is variable, with influencing factors including haemophilia severity and experience of pain. A recent study indicates a need to balance burden of treatment with protection against bleeds.© Shutterstock
The impact of infusion frequency on health-related quality of life in people with haemophilia is variable, with influencing factors including haemophilia severity and experience of pain. A recent study indicates a need to balance burden of treatment with protection against bleeds.© Shutterstock

Results of the regression analysis (coefficients, 95% confidence intervals)Values >1.0 represent positive associations (e.g. having a target joint is strongly associated with major bleeds); values <1.0 represent negative associations (e.g. having haemophilia B is negatively associated with major bleeds)

EQ-5D-3L FULL MODELBEST MODELMINOR BLEEDS FULL MODELBEST MODELMAJOR BLEEDS FULL MODELBEST MODEL
(Intercept)1.6536*** (1.3891, 1,9794)1.5907*** (1.4018, 1.808)2.4910*** (1.5097, 4.04772.4330*** (1.5911, 3.6499)0.2292* (0.0524, 0.8669)0.2959* (0.1195, 0.7238)
Age0.9981 (0.9956, 1.0006)—0.9984 (0.9927, 1.004)—1.0199*** (1.0088, 1.0309)1.0214*** (1.0110, 1.0317)
Having a target joint0.9679 (0.9147, 1.0242)—1.6486*** (1.3995, 1.9484)1.6573*** (1.4130, 1.9506)2.2315*** (1.5382, 2.2098)2.3001*** (1.59.88, 3.3808)
Primary prophylaxis (vs secondary)1.0497* (0.9979, 1.1039)1.0447* (0.9943, 1.0973)0.9601 (0.8439, 1.0938)—0.9992 (0.7624, 1.3190)—
Number of concomitant diseases1.0051 (0.9790, 1.0324)—1.0298 (0.9740, 1.0873)—1.0356 (0.9330, 1.1451)—
Number of hospitalisations0.9647* (0.9329, 0.9977)0.9612* (0.9306, 0.9932)1.0712*** (1.0357, 1.1064)1.0683*** (1.0377, 1.0976)1.0588 (0.9920, 1.1266)1.0541 (0.9901, 1.1181)
High adherence0.9917 (0.9446, 1.0411)—0.8554* (0.7512, 0.9753)0.8463* (0.7444, 0.9631)0.6817** (0.5198, 0.8955)0.6723** (0.5141, 0.8804)
Having haemophilia B0.9996 (0.9275, 1.0790)—1.0222 (0.853, 1.2179)—0.6977 (0.4408, 1.0620)0.6877 (0.4345, 1.0435)
Increasing infusion rate/year0.9999 (0.9989, 1.0009)0.9997 (0.9988, 1.0007)0.9968* (0.9936, 1.0000)0.9967* (0.9936, 0.9999)0.9977 ((0.9885, 1.0073)0.9955* (0.9921, 0.9989)
Mild chronic pain0.9271 (0.7602, 1.1201)0.8824 (0.7349, 1.0577)1.0762 (0.6296, 1.9593)1.0988 (0.6300, 1.9316)2.6814 (0.6259, 12.7098)2.1879*** (1.4188, 3.4933)
Moderate chronic pain0.8994 (0.6869, 1.1756)0.8344 (0.6590, 1.0556)1.8156** (1.0213, 3.2642)1.8877** (1.0723, 3.3572)4.2172* (0.9855, 20.1387)3.308*** (2.0707, 5.4543)
Severe chronic pain0.1826*** (0.0969, 0.3437)0.1788*** (0.1217, 0.2664)2.5249 (0.6292, 9.6216)3.6750* (1.1677, 10.6275)4.3910 (0.4313, 45.1077)3.8228*** (1.9093, 7.545)
Infusion rate/year * mild chronic pain1.0000 (0.9987, 1.0014)1.0002 (0.9989, 1.0016)1.0023 (0.9981, 1.0065)1.0024 (0.9982, 1.0065)0.9983 (0.9872, 1.0094)—
Infusion rate/year * moderate chronic pain0.9996 (0.998, 1.0012)0.9999 (0.9985, 1.0014)0.9968 (0.9968, 1.0048)1.0007 (0.9967, 10046)1.0007 (0.9967, 10046)—
Infusion rate/year * severe chronic pain1.0045* (1.0003, 1.0087)1.0045** (1.0015, 1.0075)0.9950 (0.9853, 1.0046)0.9928* (0.9841, 1.0014)0.9978 (0.9819, 1.10135)—

Demographics of the study group (n=48)

SUBSET (N=338)CHESS DATA (1,285)
Agemean (SD)30.86 (12.07)35.94 (14.70)
median (range)27 (18–67)32 (18–88)
Haemophilia typeA283 (84%)996 (77.5%)
B55 (16%)289 (22.5%)
Number of patients with target jointYes200 (59.2%)768 (59.8%)
No138 (40.8%)517 (40.2%)
Number of comorbiditiesmean (SD)0.80 (1.28)0.94 (1.33)
median0 (0–12)1 (0–12)
Number of admissionsmean (SD)0.61 (1.43)0.76 (1.46)
median0 (0–15)0 (0–15)
Treatment strategyprimary PPX†123 (36%)217 (16.9%)
secondary PPX†215 (64%)1068 (83.1%)
Number of prescribed infusions per yearmean (SD)134.45 (42.40)124.30 (50.05)
median156 (52–364)136.71 (52–364)
Weekly infusion rate††130 (9%)145 (21%)
1.46 (2%)10 (1%)
297 (29%)198 (29%)
3179 (53%)276 (40%)
3.519 (6%)35 (5%)
55 (1%)20 (3%)
61 (<1%)4 (1%)
71 (<1%)1 (<1%)
Adherencehigh117 (35%)773 (60.2%)
low221 (65%)512 (39.8%)
Chronic pain ratingnone121 (36%)461 (35.9%)
mild139 (41%)474 (36.9%)
moderate71 (21%)301 (23.4%)
high7 (2%)49 (3.8%)
eISSN:
2055-3390
Lingua:
Inglese
Frequenza di pubblicazione:
Volume Open
Argomenti della rivista:
Medicine, Basic Medical Science, other, Clinical Medicine, Pharmacy, Pharmacology
Feed RSS della rivista